Literature DB >> 29634414

PTPN12 Affects Nasopharyngeal Carcinoma Cell Proliferation and Migration Through Regulating EGFR.

Qinghai Lin1, Huige Wang1, Xinqiang Lin1, Wenrui Zhang1, Shuhua Huang1, Yandan Zheng1.   

Abstract

OBJECTIVE: Nasopharyngeal carcinoma (NPC) shows the leading morbidity in otorhinolaryngological malignant tumor. It is a common malignancy in China with obvious reginal distribution. NPC is a polygenic disease that is affected by numerous factors. Protein tyrosine phosphatase nonreceptor type 12 (PTPN12) regulates multiple tumor proliferation and development, including breast cancer and colon cancer. However, the role of PTPN12 in NPC occurrence and development has not been elucidated. PATIENTS AND METHODS: NPC cell line CNE2 was cultured in vitro and divided into three groups, including control, empty plasmid, and PTPN12 groups. PTPN12 mRNA and protein expressions were tested by real-time polymerase chain reaction and Western blot. CNE2 cell proliferation was detected by MTT assay. Cell migration was determined by wound healing assay. Cell apoptosis was evaluated by caspase 3 activity detection. Epidermal growth factor receptor (EGFR) expression was assessed by Western blot.
RESULTS: PTPN12 plasmid transfection increased PTPN12 mRNA and protein expressions, suppressed cell proliferation and migration, reduced EGFR level, and enhanced caspase 3 activity compared with control and empty plasmid groups (p < 0.05).
CONCLUSIONS: PTPN12 regulates NPC proliferation and migration through negative regulating EGFR. It could be treated as a molecular target for NPC diagnosis and prognosis analysis.

Entities:  

Keywords:  EGFR; PTPN12; migration; nasopharyngeal carcinoma; proliferation

Mesh:

Substances:

Year:  2018        PMID: 29634414     DOI: 10.1089/cbr.2017.2254

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  7 in total

1.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

2.  High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.

Authors:  Sören A Weidemann; Charlotte Sauer; Andreas M Luebke; Christina Möller-Koop; Stefan Steurer; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Till S Clauditz; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Christoph Fraune; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Asmus Heumann
Journal:  BMC Cancer       Date:  2019-10-12       Impact factor: 4.430

3.  Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.

Authors:  Mi Tian; Tao Wang; Peng Wang
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 4.  Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy.

Authors:  Xiaolong Tang; Chumei Qi; Honghong Zhou; Yongshuo Liu
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

5.  Transthyretin-induced increase in circ_0007411 represses neovascularization of human retinal microvascular endothelial cells in hyperglycemia via the miR-548m/PTPN12/SKP1/EGFR pathway.

Authors:  Di Hu; Yikun Tian; Lu Ye; Yu Xin; Jun Shao
Journal:  Ann Transl Med       Date:  2022-05

6.  Downregulation of secreted frizzled-related protein 4 inhibits hypoxia/reoxygenation injury in diabetic cardiomyocytes by protein tyrosine phosphatase nonreceptor type 12.

Authors:  Zhifeng Bai; Xiuhong Hao
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

7.  Progress in the correlation between PTPN12 gene expression and human tumors.

Authors:  Yu-Hu Huo; Ya-Ni Wang; Ling-Bing Meng; Ai-Li Zhang; Bin Liu
Journal:  Medicine (Baltimore)       Date:  2020-06-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.